Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster.
Antigens, Viral
Chickenpox
/ prevention & control
Chickenpox Vaccine
/ administration & dosage
Herpes Zoster
/ prevention & control
Herpes Zoster Vaccine
/ administration & dosage
Herpesvirus 3, Human
/ drug effects
Humans
Incidence
Measles-Mumps-Rubella Vaccine
United States
/ epidemiology
Vaccination
Vaccines, Attenuated
/ administration & dosage
Vaccines, Combined
anti-viral therapy
fluorescent antibody to membrane antigen (FAMA)
latency
leukemia
reactivation
varicella zoster virus
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
30 09 2021
30 09 2021
Historique:
entrez:
30
9
2021
pubmed:
1
10
2021
medline:
11
3
2022
Statut:
ppublish
Résumé
Michiaki Takahashi developed the live attenuated varicella vaccine in 1974 . This was the first, and is still the only, herpesvirus vaccine. Early studies showed promise, but the vaccine was rigorously tested on immunosuppressed patients because of their high risk of fatal varicella; vaccination proved to be lifesaving. Subsequently, the vaccine was found to be safe and effective in healthy children. Eventually, varicella vaccine became a component of measles mumps rubella vaccine, 2 doses of which are administered in the USA to ~90% of children. The incidence of varicella has dropped dramatically in the USA since vaccine-licensure in 1995. Varicella vaccine is also associated with a decreased incidence of zoster and is protective for susceptible adults. Today, immunocompromised individuals are protected against varicella due to vaccine-induced herd immunity. Latent infection with varicella zoster virus occurs after vaccination; however, the vaccine strain is impaired for its ability to reactivate.
Identifiants
pubmed: 34590140
pii: 6378094
doi: 10.1093/infdis/jiaa573
pmc: PMC8482020
doi:
Substances chimiques
Antigens, Viral
0
Chickenpox Vaccine
0
Herpes Zoster Vaccine
0
Measles-Mumps-Rubella Vaccine
0
Vaccines, Attenuated
0
Vaccines, Combined
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
S387-S397Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK093094
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
JAMA. 2004 Feb 18;291(7):851-5
pubmed: 14970064
Pediatrics. 1987 Oct;80(4):465-72
pubmed: 2821476
J Pediatr. 1990 Feb;116(2):184-9
pubmed: 2153790
J Trop Med Hyg. 1963 Dec;66:311-5
pubmed: 14090785
Clin Microbiol Rev. 2013 Oct;26(4):728-43
pubmed: 24092852
N Engl J Med. 1969 May 29;280(22):1191-4
pubmed: 4181206
Vaccine. 2018 Jun 22;36(27):3890-3893
pubmed: 29807711
Microbiol Sci. 1985 Aug;2(8):249-54
pubmed: 2856380
Vaccine. 2017 Dec 19;35(52):7231-7239
pubmed: 29174682
J Infect Dis. 1996 Feb;173(2):450-3
pubmed: 8568309
Expert Rev Vaccines. 2017 Apr;16(4):391-400
pubmed: 28276305
MMWR Recomm Rep. 2007 Jun 22;56(RR-4):1-40
pubmed: 17585291
JAMA. 1984 Jul 20;252(3):355-62
pubmed: 6330386
Clin Infect Dis. 2015 Aug 15;61(4):536-44
pubmed: 25882301
J Infect Dis. 1988 Jul;158(1):132-7
pubmed: 2839577
Clin Infect Dis. 2011 Sep;53(5):405-10
pubmed: 21844022
Clin Infect Dis. 2015 Apr 1;60(7):1068-74
pubmed: 25452596
J Clin Immunol. 2015 Nov;35(8):754-60
pubmed: 26515615
J Infect Dis. 2011 Feb 1;203(3):312-5
pubmed: 21208922
Lancet. 1974 Nov 30;2(7892):1288-90
pubmed: 4139526
BMJ Case Rep. 2016 May 04;2016:
pubmed: 27147629
Expert Rev Vaccines. 2019 Aug;18(8):793-811
pubmed: 31318605
JAMA. 1994 Feb 2;271(5):375-81
pubmed: 8283587
Lancet. 2007 Apr 7;369(9568):1232
pubmed: 17416267
Pediatrics. 2019 Sep;144(3):
pubmed: 31471448
Vaccine. 2002 Jun 7;20(19-20):2500-7
pubmed: 12057605
J Infect Dis. 2013 Dec 1;208(11):1859-68
pubmed: 23922376
N Engl J Med. 1966 Jan 27;274(4):181-5
pubmed: 4285450
Nat Rev Dis Primers. 2015 Jul 02;1:15016
pubmed: 27188665
Hum Vaccin Immunother. 2014;10(1):146-9
pubmed: 23982221
N Engl J Med. 1974 Jan 31;290(5):243-5
pubmed: 4358055
J Med Virol. 2004 Jan;72(1):174-9
pubmed: 14635028
J Infect Dis. 1995 Sep;172(3):706-12
pubmed: 7658062
N Engl J Med. 1984 May 31;310(22):1409-15
pubmed: 6325909
Postgrad Med J. 1985;61 Suppl 4:17-22
pubmed: 3939152
Biken J. 1975 Mar;18(1):25-33
pubmed: 167707
Postgrad Med J. 1985;61 Suppl 4:61-7
pubmed: 3014479
J Infect Dis. 1996 Nov;174 Suppl 3:S330-4
pubmed: 8896541
N Engl J Med. 1962 Aug 23;267:369-76
pubmed: 14494142
Pediatrics. 2019 Dec;144(6):
pubmed: 31776194
Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):E2403-12
pubmed: 27078099
Proc R Soc Med. 1965 Jan;58:9-20
pubmed: 14267505
Nihon Rinsho. 1985 Jul;43(7):1535-41
pubmed: 2997506
Pediatrics. 2019 Jul;144(1):
pubmed: 31182552
Infect Dis Clin North Am. 1996 Sep;10(3):595-608
pubmed: 8856354
N Engl J Med. 1991 Nov 28;325(22):1545-50
pubmed: 1658650
JAMA. 2004 Aug 11;292(6):704-8
pubmed: 15304467
Curr Top Microbiol Immunol. 2010;342:359-72
pubmed: 20232192
Infect Dis Clin North Am. 1996 Sep;10(3):469-88
pubmed: 8856348
Pediatrics. 1986 Oct;78(4 Pt 2):736-41
pubmed: 3020493
J Infect Dis. 2008 Mar 1;197(5):635-7
pubmed: 18260760